Sangamo BioSciences | SGMO - Cash And Equivalent


Sangamo BioSciences reported $38.34M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 12.04B 2.91B Mar/2026
Bayer EUR 6.67B 774M Dec/2025
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 12.43M 78.16M Mar/2026
CSL USD 2.16B 633M Jun/2025
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Omeros USD 1.9M 2.36M Jun/2025
Pfizer USD 1.7B 561M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026